The ADAPTABLE Study

Aspirin Dosing: A Patient-Centric Trial Assessing Benefits and Long-Term Effectiveness
Significance of the Project

Every year 720,000 Americans have a heart attack, and nearly 380,000 die of atherosclerotic cardiovascular disease (ASCVD), also known as hardening of the arteries. Many patients who survive develop heart failure, stroke, and/or other cardiovascular complications.

These patients often experience chest pain, shortness of breath, and fatigue, which can lead to significant distress and worsening quality of life. Rates of mental health illnesses such as depression are high among both these patients and their caregivers; rates of depression may approach 66% in post-myocardial infarction (MI) patients. Coronary heart disease alone costs the US $108.9 billion each year.

Aspirin, also known as acetylsalicylic acid (ASA), is the most commonly prescribed medication for cardiovascular disease. It significantly reduces outcomes such as heart attack and stroke in patients with previous cardiovascular events and/or atherosclerosis at a cost of less than one cent per day.

However, despite a history of robust evidence generation in patients with cardiovascular disease, there are still critical unanswered question on what dosage of aspirin is most effective and safe. Despite dozens of clinical trials involving more than 200,000 patients, the optimal dose of aspirin has not been determined in direct comparative-effectiveness trials.

Summary of the Project

ADAPTABLE studied the effectiveness and safety of the two most common aspirin doses, and it served as the demonstration project for clinical trials in the Patient-Centered Outcomes Research network (PCORnet), funded by the Patient-Centered Outcomes Research Institute (PCORI).

ADAPTABLE is a pragmatic clinical trial in which 15,076 patients with established ASCVD and at high risk for ischemic events (reduced bloodflow to tissues) were randomized in a 1:1 fashion to receive an aspirin dose of 81 mg/day vs 325 mg/day.

The primary endpoint is a composite of all-cause death, hospitalization for MI, or hospitalization for stroke. The primary safety endpoint is hospitalization for major bleeding with an associated blood product transfusion.

Summary of Results

Results published in May 2021 found no differences in cardiovascular events or major bleeding between patients who took the 81 mg and to those who took 325 mg of aspirin daily.

In addition, this study—as the first demonstration project for pragmatic clinical trials using PCORnet—held important lessons regarding identifying a large cohort of eligible patients; engaging, recruiting, and randomly assigning patients; and performing critical follow-up.
Impact of the Project

Clinical

ADAPTABLE answers the question about the most effective and safe dose of aspirin in patients with ASCVD, informing clinical practice guidelines and assisting clinicians who care for patients with ASCVD.

In addition, the methods and processes of ADAPTABLE have informed and changed how research can be done within health systems. The use of a computable phenotype led to the identification of a large potentially eligible population of patients with ASCVD in the study centers. Because aspirin is an over-the-counter medication and the trial is an open label study, direct-to-patient approach strategies were used to initially approach a large group (~450,000) of potential participants.

Utilizing an electronic consent process and web-based patient portal, 15,076 participants were enrolled either virtually or via research coordinator/investigator assistance at a study center. The patient portal was also used for study retention and follow-up, obviating the need for participants to return to the study centers on a routine basis.

The nine Clinical Data Research Networks and their patient partners around the country were involved in every aspect of study design and conduct, including protocol review, design of patient-facing materials and the electronic consent form, and participant newsletters and blogs.

A Patient-Powered Research Network called Health eHeart centered at the University of California, San Francisco was deeply involved in all aspects of our patient engagement plans.

Community

ADAPTABLE has defined the optimal dose of a low-cost drug (ASA) that can enhance health promotion and disease prevention in communities or populations.

Using a low-cost, readily available over-the-counter drug reduces stroke and heart attack risk in patients with ASCVD, improving quality-of-life and life expectancy.

Economic

ASA is a low-cost, over-the-counter option for the treatment of ASCVD and the prevention of heart attacks and stroke in those at high risk.

As such, it can significantly reduce the financial burden of of a chronic disease such as ASCVD.

About the Research Team

Adrian Hernandez, MD - Principal Investigator
- Vice Dean and Executive Director, Duke Clinical Research Institute
- Professor of Medicine
- Duke Health Cardiology Professor
- Executive Core Faculty Member, Duke-Margolis Center for Health Policy.

W. Schuyler Jones, MD - Principal Investigator
- Assistant Professor of Medicine, Duke School of Medicine
- Associate Professor in Population Health Sciences
- Member of the Duke Clinical Research Institute

Janis Curtis, MSPH
- Associate Director of Clinical Data Research Networks, Duke Clinical & Translational Science Institute
**Notice of funding from PCORI**

- **MAY 2015**: Notice of funding from PCORI
- **APR 2016**: First participant enrolled

**Enrollment Begins**

- **JAN 2016**: Beginning date of project

**Enrollment Ends**

- **JUNE 2019**: Last patient enrolled

**STUDY ENROLLMENT AND PATIENT VISITS**

- **JUNE 2020**: Last patient last visit
- **FEB 2021**: Study database locked
- **MAR 2021**: Final results available for review

**Anticipated Future Milestones**

- **JUNE 2020**: Last patient last visit
- **FEB 2021**: Study database locked
- **MAR 2021**: Final results available for review

**Official project end date**

- **FEB 2022**: Official project end date

**Future Directions**

- **Multiple sub-studies are planned**

**Study database locked**

- **MAY 2021**: Results presented to participants, team, and public

**Publication in major medical journal**

- **MAY 2021**: Final results presented to participants, team, and public

**Publication**

- **MAY 2021**: Publication in major medical journal

**Presentation of Results**

- **MAY 2021**: Final results presented to participants, team, and public

**Project End**

- **FEB 2022**: Official project end date

**Future Directions**

- **Multiple sub-studies are planned**
Translational Science Benefits Summary

**CLINICAL**

**Drugs:**
Aspirin to prevent ischemic events in patients with ASCVD at high risk

**Guidelines:**
Methods and process of ADAPTABLE have changed how research can be done within health systems

**COMMUNITY**

**Life Expectancy & Quality of Life:**
Using a low-cost, readily-available over-the-counter drug reduces ischemic events and their sequelae in patients with ASCVD improving quality of life and life expectancy

**ECONOMIC**

**Cost Savings:**
Aspirin is a low-cost option for the treatment of ASCVD and the prevention of ischemic events in those at high risk

**Societal & Financial Cost of Illness:**
Low-cost medication can significantly reduce the financial burden of a chronic disease (ASCVD)

**Disease Prevention & Reduction:**
Study has defined the optimal dose of a low-cost drug that can enhance health promotion and disease prevention in communities or populations
CTSA Resources Used

<table>
<thead>
<tr>
<th>Core</th>
<th>Type of Service</th>
</tr>
</thead>
<tbody>
<tr>
<td>Network Capacity Core</td>
<td>Expertise and access to Clinical Data Research Networks (STAR Network)</td>
</tr>
<tr>
<td>(Research Networks and Recruitment Innovation)</td>
<td></td>
</tr>
<tr>
<td>Informatics Core</td>
<td>Facilitated participation in STAR Network</td>
</tr>
<tr>
<td>Participant Clinical Interactions Core</td>
<td>Study start-up; participant recruitment; electronic health record expertise</td>
</tr>
</tbody>
</table>